Opinion|Videos|July 23, 2026 (Updated: July 16, 2026)
Defining Alzheimer's Disease Agitation: Diagnostic Criteria, Symptoms, and Disease Course
Kavita Nair leads the discussion on defining Alzheimer's disease agitation.
Advertisement
Episodes in this series
Kavita Nair leads the discussion on defining Alzheimer's disease agitation. Anton Porsteinsson outlines IPA provisional diagnostic criteria (2015, made permanent 2023): agitation must occur in context of cognitive impairment, include ≥1 of 3 behavioral manifestations (excessive motor activity, verbal aggression, physical aggression), persist ≥2 weeks, cause distress and disability, and not be attributable to another condition. Agitation can present as early as pre-dementia stages (MCI) and typically peaks during moderate to early severe stages.
Advertisement
Related to this article
In experiments at MD Anderson, rising CD70 helps mantle cell lymphoma evade immunity; a CD70×CD3 bispecific restores T-cell killing and prolongs survival in resistant models.
Upper-extremity synovial sarcoma required more staged surgery, while lower-extremity disease carried more complications and metastases.
In the US alone, 1.1 million individuals are living with the progressive neurodegenerative movement disorder, and 90,000 are diagnosed each year.
The National Comprehensive Cancer Network update on mantle cell lymphoma puts covalent BTK inhibitors, MRD testing, and TP53 sequencing at the center of frontline care, while adding pirtobrutinib and a pair of CAR T-cell therapies for disease that progresses on a BTK inhibitor.
CDC's David A. Siegel, MD, MPH, on rising cancer diagnoses, falling deaths, and where CDC's cancer control resources go next.
CDC's Jane Henley, MSPH, explains what's behind falling lung cancer deaths and why 4 in 5 eligible adults still aren't getting screened.
Machine learning identified age, BMI, income, and reproductive factors as key predictors of overactive bladder risk among US women.
Tammy Lundstrom, MD, JD, discusses the new childhood vaccine order, single-dose MMR access concerns, and the measles resurgence.
Advertisement
Advertisement
Trending on AJMC
1
Tavapadon for Parkinson Disease Approved by FDA
2
Medicare Cap Eases Patient Costs as Negotiation Squeezes Practices
3
Baricitinib Approved for Severe Alopecia Areata in Adolescents
4
Access and Innovation in North Carolina’s Research Triangle
5